GlassScriptPhysician profile
Brandon Blanken
NPI 1134758907
$11,627.49
in general payments reported to CMS, 2019-2025
31 companies · $4,209 in 2025
The $4,209 reported for 2025 was more than what 95% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $867 · 2023: $3,170 · 2024: $3,382 · 2025: $4,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,561 · Travel and Lodging: $5,050 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.83 |
| Travel and Lodging | $5,050.16 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,080.02 | 2022-2025 | Prostep, Prophecy, Salvation |
| Arthrex, INC. | $2,236.98 | 2024-2025 | |
| Supreme Orthopedic Systems, LLC | $1,344.24 | 2024-2025 | |
| Orthofix Medical, INC. | $1,114.33 | 2024 | Truelok |
| Trilliant Surgical LLC. | $578.97 | 2025 | Arsenal Ankle, Arsenal Sinus Support Plate |
| Kerecis Limited | $305.00 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $295.43 | 2023-2025 | Inceptiv, Closurefast |
| Fortis Surgical, LLC | $278.86 | 2023-2025 | |
| Lifenet Health | $232.99 | 2024-2025 | Theragenesis Wound Matrix |
| Smith+Nephew, INC. | $225.28 | 2024-2025 | Grafix Pl, Stravix Mesh, Oasis Micro |
| Convatec INC. | $203.26 | 2023-2025 | |
| Integra Lifesciences Corporation | $171.20 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Horizon Therapeutics Plc | $154.33 | 2023 | Krystexxa |
| Sanara Medtech INC. | $149.30 | 2023 | Celleraterx |
| Novastep INC. | $141.99 | 2025 | Nexis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $132.70 | 2023-2024 | Nuzyra |
| Nuo Therapeutics | $132.15 | 2025 | |
| Mimedx Group, INC. | $118.76 | 2025 | |
| Treace Medical Concepts, INC. | $112.99 | 2024 | |
| Abbott Laboratories | $102.94 | 2023 | Diamondback Peripheral |
| Paragon 28, INC. | $92.68 | 2023 | Additive Orthopedics |
| Curonix LLC | $87.27 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Linvatec Corporation | $83.27 | 2023 | 5ms, Colink Vallux, Colink Afx |
| International Life Sciences | $66.46 | 2024 | Flexband |
| Globus Medical, INC. | $34.40 | 2025 | Senza |
| Ani Pharmaceuticals, INC. | $30.45 | 2025 | Purified Cortrophin Gel |
| Averitas Pharma INC. | $26.91 | 2024 | Qutenza |
| Pacira Pharmaceuticals Incorporated | $25.57 | 2024 | Iovera, Exparel |
| Acumed LLC | $24.96 | 2024 | Acumed, Osteomed |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.77 | 2025 | Jublia |
| Trice Medical, INC. | $21.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Blanken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.